{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:19:54Z","timestamp":1791652794996,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40744-025-00755-9","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T02:50:30Z","timestamp":1741661430000},"page":"469-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Experience with an Adalimumab Biosimilar (ABP\u00a0501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-9187","authenticated-orcid":false,"given":"Ran","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-5809","authenticated-orcid":false,"given":"James M.","family":"Haughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1480-040X","authenticated-orcid":false,"given":"Emily J.","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4436-1537","authenticated-orcid":false,"given":"Delphine","family":"Courmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-7436","authenticated-orcid":false,"given":"Waldemar","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-4733","authenticated-orcid":false,"given":"Rachael H.","family":"Meadows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-1021","authenticated-orcid":false,"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-979X","authenticated-orcid":false,"given":"Stanley","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"5","key":"755_CR1","first-page":"721","volume":"35","author":"F Ferro","year":"2017","unstructured":"Ferro F, Elefante E, Luciano N, Talarico R, Todoerti M. One year in review 2017: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(5):721\u201334.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"755_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","volume":"17","author":"D Mauro","year":"2021","unstructured":"Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021;17(7):387\u2013404.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"755_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18(4):205\u201316.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"755_CR4","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3906\/sag-2011-235","volume":"51","author":"H Emmungil","year":"2021","unstructured":"Emmungil H, Ilgen U, Direskeneli RH. Autoimmunity in psoriatic arthritis: pathophysiological and clinical aspects. Turk J Med Sci. 2021;51(4):1601\u201314.","journal-title":"Turk J Med Sci"},{"key":"755_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","volume":"49","author":"Y Liang","year":"2017","unstructured":"Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1\u20138.","journal-title":"Curr Opin Immunol"},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.12688\/f1000research.14956.1","volume":"7","author":"L Garcia-Montoya","year":"2018","unstructured":"Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res. 2018;7:1512.","journal-title":"F1000Res"},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.12688\/f1000research.19144.1","volume":"8","author":"DV Ocampo","year":"2019","unstructured":"Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665.","journal-title":"F1000Res"},{"issue":"10055","key":"755_CR8","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"10136","key":"755_CR9","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"4","key":"755_CR10","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.","journal-title":"Cells"},{"issue":"1","key":"755_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13933","volume":"1442","author":"M Lata","year":"2019","unstructured":"Lata M, Hettinghouse AS, Liu CJ. Targeting tumor necrosis factor receptors in ankylosing spondylitis. Ann N Y Acad Sci. 2019;1442(1):5\u201316.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"755_CR12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Se\u00a0ction 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"755_CR13","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","volume":"110","author":"J Coghlan","year":"2021","unstructured":"Coghlan J, He H, Schwendeman AS. Overview of Humira\u00ae biosimilars: current european landscape and future implications. J Pharm Sci. 2021;110(4):1572\u201382.","journal-title":"J Pharm Sci"},{"key":"755_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.vhri.2014.07.008","volume":"4","author":"K Kruntoradova","year":"2014","unstructured":"Kruntoradova K, Klimes J, Sedova L, Stolfa J, Dolezal T, Petrikova A. Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Value Health Reg Issues. 2014;4:100\u20136.","journal-title":"Value Health Reg Issues"},{"key":"755_CR15","unstructured":"Amgen. European Commission approves AMGEVITA\u2122 (biosimilar adalimumab) for the treatment of certain inflammatory diseases. 23 March 2017. https:\/\/www.prnewswire.com\/news-releases\/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases-300428713.html. Accessed  23 Aug 2023."},{"issue":"11","key":"755_CR16","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0117","volume":"12","author":"V Abitbol","year":"2023","unstructured":"Abitbol V, Benkhalifa S, Habauzit C, Marotte H. Navigating adalimumab biosimilars: an expert opinion. J Comp Eff Res. 2023;12(11):e230117.","journal-title":"J Comp Eff Res"},{"issue":"10","key":"755_CR17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP\u00a0501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase\u00a0III equivalence study. Ann Rheum Dis. 2017;76(10):1679\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"755_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-019-1857-3","volume":"21","author":"S Cohen","year":"2019","unstructured":"Cohen S, Pablos JL, Pavelka K, et al. An open-label extension study to demonstrate long-term safety and efficacy of ABP\u00a0501 in patients with rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):84.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"755_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","volume":"76","author":"K Papp","year":"2017","unstructured":"Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP\u00a0501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase\u00a0III study. J Am Acad Dermatol. 2017;76(6):1093\u2013102.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"755_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12325-023-02712-w","volume":"41","author":"R Jin","year":"2024","unstructured":"Jin R, Nduka C, Courmier D, et al. Real-world experience of adalimumab biosimilar (ABP\u00a0501) use in patients with inflammatory bowel disease in Europe. Adv Ther. 2024;41(1):331\u201348.","journal-title":"Adv Ther"},{"issue":"11","key":"755_CR21","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"755_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy JD, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"755_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"755_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"5","key":"755_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"755_CR27","volume-title":"Stata statistical software: release 17","author":"StataCorp","year":"2021","unstructured":"StataCorp. Stata statistical software: release 17. College Station: StataCorp; 2021."},{"key":"755_CR28","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of Conduct 2024 [Issued September 2024]. https:\/\/www.ephmra.org\/sites\/default\/files\/2024-09\/2024%20EPHMRA%20Code%20of%20Conduct%20Final.pdf. Accessed 15 Oct 2024."},{"key":"755_CR29","unstructured":"US Department of Health and Human Services. Summary of the HIPAA Privacy Rule 2003. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed 15 Oct 2024."},{"key":"755_CR30","unstructured":"Health Information Technology (HITECH). Health information technology (HITECH) Act 2019. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed  23 Aug 2023."},{"key":"755_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104467","volume":"149","author":"FC Ara\u00fajo","year":"2019","unstructured":"Ara\u00fajo FC, Gon\u00e7alves J, Fonseca JE. Biosimilars in rheumatology. Pharmacol Res. 2019;149:104467.","journal-title":"Pharmacol Res"},{"issue":"2","key":"755_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","volume":"8","author":"JM Carrascosa","year":"2018","unstructured":"Carrascosa JM, Jacobs I, Petersel D, Strohal R. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther (Heidelb). 2018;8(2):173\u201394.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"755_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52: 151939.","journal-title":"Semin Arthritis Rheum"},{"key":"755_CR34","unstructured":"Padda IS, Bhatt R, Rehman O, Parmar M. Biosimilars use in medicine for inflammatory diseases. StatPearls. Treasure Island (FL): StatPearls; 2024."},{"issue":"12","key":"755_CR35","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1080\/14712598.2022.2070428","volume":"22","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Geat D, Armeni P, Bellinato F, Maurelli M, Girolomoni G. Cost per responder of adalimumab biosimilars MSB11022 and ABP\u00a0501 versus the originator and methotrexate in chronic plaque psoriasis. Expert Opin Biol Ther. 2022;22(12):1579\u201384.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"755_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70(1):60\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"755_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.dld.2023.06.022","volume":"56","author":"P Wetwittayakhlang","year":"2024","unstructured":"Wetwittayakhlang P, Karkout K, Wongcha-Um A, et al. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: a prospective observational study. Dig Liver Dis. 2024;56(1):35\u201342.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"755_CR38","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10198-019-01054-1","volume":"20","author":"T Grochtdreis","year":"2019","unstructured":"Grochtdreis T, Dams J, K\u00f6nig H-H, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933\u201344.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"755_CR39","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/ijerph14040426","volume":"14","author":"MB Huber","year":"2017","unstructured":"Huber MB, Felix J, Vogelmann M, Leidl R. Health-related quality of life of the general German population in 2015: results from the EQ-5D-5L. Int J Environ Res Public Health. 2017;14(4):426.","journal-title":"Int J Environ Res Public Health"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00755-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T12:43:22Z","timestamp":1747399402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00755-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00755-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emily J Goddard, James M Haughton, James Piercy and Rachael H Meadows are employees of Adelphi Real World. Ran Jin and Waldemar Radziszewski are employees of Amgen Inc., Thousand Oaks, CA, USA, and may own stock and\/or hold stock options in Amgen Inc. Delphine Courmier was an employee of Amgen Inc., Thousand Oaks, CA, USA at the time of this study. At the time of publication, Delphine\u00a0Courmier was an employee of Organon, Jersey City, NJ, USA. Stanley Cohen is an investigator and consultant for Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data collection methodology and survey questionnaires were reviewed and approved by the Western Institutional Review Board (protocol numbers #1-1253914-1 [RA 2020 wave], #20210318 [SpA]) or Pearl Institutional Review Board (protocol numbers #21-ADRW-104 [RA 2021\/2022 wave], #21-ADRW-124 [PsO]). Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines []; and the survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [] and Health Information Technology for Economic and Clinical Health Act legislation [], and in accordance with the principles stated in the Declaration of Helsinki. Using a checkbox, patients provided informed consent take part in the survey, and for the use of their anonymized and aggregated data for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}